World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 1 February 2016
Main ID:  NCT02246348
Date of registration: 17/09/2014
Prospective Registration: No
Primary sponsor: Echosense Ltd.
Public title: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Scientific title: Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)
Date of first enrolment: September 2014
Target sample size: 5
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT02246348
Study type:  Interventional
Study design:  Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic  
Phase:  N/A
Countries of recruitment
Israel
Contacts
Name:     Alexsandra Balbir, Dr
Address: 
Telephone:
Email:
Affiliation:  Rambam Health Care Campus
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Able and willing to give signed informed consent prior to enrollment

2. Male or female, = 18 years of age

3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den
Hoogen 2013): Score = 9.

4. Patients with RHC data available from measurement within 3 weeks prior to TPD
assessment

5. No change in or initiation of PAH specific therapy between the last RHC and TPD

Exclusion Criteria:

1. People unable or unwilling to give informed consent.

2. PCWP or LVEDP > 15 mmHg

3. Any PH etiology outside Group 1 (Dana Point, 2008)

4. Pregnant women

5. Patients having severe chest wall deformity



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Pulmonary Hypertension
Systemic Sclerosis
Intervention(s)
Radiation: Doppler ultrasound
Primary Outcome(s)
Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC. [Time Frame: 12 month]
Secondary Outcome(s)
Secondary ID(s)
DOP22_2
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history